scv13dza
                     
CUSIP No.
  
89235K105 
Schedule 13D
 Page  
1 
   of   
11 
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO
RULES 13d-1(a) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(a)
(Amendment No. 1)1

Achillion Pharmaceuticals Inc.
(Name of Issuer)
Common Stock, par value $0.001
(Title of Class of Securities)
00448Q201
(CUSIP Number)
Jarlyth H. Gibson, Assistant Compliance Officer 617-951-9493
C/o Advent International Corporation, 75 State Street, Boston, MA 02109
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
August 12, 2008
(Date of Event Which Requires Filing of this Statement)

     If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box:. o

     Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

(Continued on following pages)
(Page 1 of 11 Pages)

1The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
 

 

                     
CUSIP No.
  
89235K105 
Schedule 13D
 Page  
2 
   of   
11 

 

           
1   NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

Advent International Corporation
     
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
  (a)   þ 
  (b)   o 
     
3   SEC USE ONLY
   
   
     
4   SOURCE OF FUNDS
   
  WC
     
5   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
   
     
6   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
  7   SOLE VOTING POWER
     
NUMBER OF   1,159,440
       
SHARES 8   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   None
       
EACH 9   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   1,159,440
       
WITH 10   SHARED DISPOSITIVE POWER
     
    None
     
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  1,159,440
     
12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
   
  o
     
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   
  4.39%
     
14   TYPE OF REPORTING PERSON*
   
  CO, IA

 

                     
CUSIP No.
  
89235K105 
Schedule 13D
 Page  
3 
   of   
11 

 

           
1   NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

Advent International Limited Partnership
     
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
  (a)   þ 
  (b)   o 
     
3   SEC USE ONLY
   
   
     
4   SOURCE OF FUNDS
   
  WC
     
5   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
   
     
6   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
  7   SOLE VOTING POWER
     
NUMBER OF   1,126,750
       
SHARES 8   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   None
       
EACH 9   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   1,126,750
       
WITH 10   SHARED DISPOSITIVE POWER
     
    None
     
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  1,126,750
     
12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
   
  o
     
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   
  4.27%
     
14   TYPE OF REPORTING PERSON*
   
  PN

 

                     
CUSIP No.
  
89235K105 
Schedule 13D
 Page  
4 
   of   
11 

 

           
1   NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

Advent Healthcare and Life Sciences II Limited Partnership
     
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

  (a)   þ 
  (b)   o 
     
3   SEC USE ONLY
   
   
     
4   SOURCE OF FUNDS
   
  WC
     
5   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
   
     
6   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
  7   SOLE VOTING POWER
     
NUMBER OF   1,045,360
       
SHARES 8   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   None
       
EACH 9   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   1,045,360
       
WITH 10   SHARED DISPOSITIVE POWER
     
    None
     
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  1,045,360
     
12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
   
  o
     
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   
  3.96%
     
14   TYPE OF REPORTING PERSON*
   
  PN

 

 

                     
CUSIP No.
  
89235K105 
Schedule 13D
 Page  
5 
   of   
11 

 

           
1   NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

Advent Healthcare and Life Sciences II Beteiligung GmbH & Co. KG
     
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
  (a)   þ 
  (b)   o 
     
3   SEC USE ONLY
   
   
     
4   SOURCE OF FUNDS
   
  WC
     
5   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
   
     
6   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Germany
       
  7   SOLE VOTING POWER
     
NUMBER OF   81,390
       
SHARES 8   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   None
       
EACH 9   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   81,390
       
WITH 10   SHARED DISPOSITIVE POWER
     
    None
     
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  81,390
     
12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
   
  o
     
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   
  0.31%
     
14   TYPE OF REPORTING PERSON*
   
  PN

 

 

                     
CUSIP No.
  
89235K105 
Schedule 13D
 Page  
6 
   of   
11 

 

           
1   NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

Advent Partners HLS II Limited Partnership
     
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
  (a)   þ 
  (b)   o 
     
3   SEC USE ONLY
   
   
     
4   SOURCE OF FUNDS
   
  WC
     
5   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
   
     
6   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
  7   SOLE VOTING POWER
     
NUMBER OF   23,186
       
SHARES 8   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   None
       
EACH 9   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   23,186
       
WITH 10   SHARED DISPOSITIVE POWER
     
    None
     
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  23,186
     
12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
   
  o
     
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   
  0.09%
     
14   TYPE OF REPORTING PERSON*
   
  PN

 

 

                     
CUSIP No.
  
89235K105 
Schedule 13D
 Page  
7 
   of   
11 

 

           
1   NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

Advent Partners Limited Partnership
     
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

  (a)   þ 
  (b)   o 
     
3   SEC USE ONLY
   
   
     
4   SOURCE OF FUNDS
   
  WC
     
5   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
   
     
6   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
  7   SOLE VOTING POWER
     
NUMBER OF   9,504
       
SHARES 8   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   None
       
EACH 9   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   9,504
       
WITH 10   SHARED DISPOSITIVE POWER
     
    None
     
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  9,504
     
12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
   
  o
     
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   
  0.04%
     
14   TYPE OF REPORTING PERSON*
   
  PN

 

 

CUSIP NO. 89235K105 Schedule 13D Page 8 of 11
Item 1. Security and Issuer
     This statement on Amendment No. 1 to Schedule 13D (“Amendment No. 1”) relates to the Reporting Persons’ beneficial ownership interest in the Common Stock, par value $0.001 per share (the “Common Stock”), of Achillion Pharmaceuticals Inc., a Delaware corporation (the “Corporation”). The address of the principal executive office of the Corporation is 300 George Street, New Haven, CT 06511. This Amendment No. 1 amends the initial statement on Schedule 13D filed with the Securities and Exchange Commission (the “Commission”) on November 8, 2006. This Amendment No. 1 is being filed by the Reporting Persons to amend Item 5. Terms defined in the Schedule 13D are used herein as so defined.
Item 5. Interest in Securities of the Issuer.
     (a) The following table sets forth the aggregate number and percentage of the Common Stock beneficially owned by each Reporting Person named in Item 2 of this statement (based upon 26,376,000 shares of Common Stock outstanding as August 13, 2008). The aggregate number and percentage of the Common Stock beneficially owned by each Reporting Person is calculated in accordance with Rule 13d-3.
                                         
                            Percentage of   # of Shares
    Number of Shares     Common Stock   Disposed of During
Reporting Person   Common Stock   Warrants   Total   Outstanding   Past 60 Days
 
Advent International
Corporation (1)(2)(3)
     1,116,432       43,008       1,159,440       4.39 %     0  
Advent International
Limited Partnership (1)
     1,084,954       41,796       1,126,750       4.27 %     0  
Advent Healthcare and
Life Sciences II Limited
Partnership (2)
     1,006,582       38,778       1,045,360       3.96 %     0  
Advent Healthcare and
Life Sciences II Beteiligung
GmbH & Co. KG (2)
     78,372       3,018       81,390       0.31 %     0  
Advent Partners HLS II
Limited Partnership (3)
     22,326       860       23,186       0.09 %     0  
Advent Partners Limited
Partnership (3)
     9,152       352       9,504       0.04 %     0  
 
Total Group
     1,116,432       43,008       1,159,440       4.39 %     0  
          (1) Advent International Corporation (“AIC”) is the General Partner of Advent International Limited Partnership (“AILP”) which in turn is the General Partner and the Managing Limited Partner of the indicated Reporting Persons. As such, AIC has the sole power to vote and dispose of the securities owned by the indicated Reporting Persons. The beneficial ownership of AIC and AILP derive from such power.

 

 

CUSIP NO. 89235K105 Schedule 13D Page 9 of 11
          (2) Advent International Corporation (“AIC”) is the General Partner of Advent International Limited Partnership (“AILP”) which in turn is the General Partner of Advent Healthcare and Life Sciences II Limited Partnership as well as the Managing Limited Partner of Advent Healthcare and Life Sciences II Beteiligung GmbH & Co. KG. As such, AIC has the sole power to vote and dispose of the securities owned by the indicated Reporting Persons. The beneficial ownership of AIC and AILP derive from such power.
          (3) AIC is the General Partner of the indicated Reporting Person. As such, AIC has the power to vote and dispose of the securities of Advent Partners HLS II Limited Partnership and Advent Partners Limited Partnership.
     (b) Each of the Reporting Persons listed in the table set forth above has sole voting and dispositive power over the Common Stock beneficially owned by it as indicated above.
     (c) On August 12, 2008 the Company issued 10,714,655 units at a price of $2.9049 per unit. Each unit consists of one share of common stock and a warrant to purchase 0.25 shares of common stock at an exercise price of $3.53 per share. This issuance reduced the Reporting Persons’ beneficial ownership from 7.41% (based upon 15,641,462 shares of Common Stock outstanding as of May 7, 2008) to 4.39%. None of the Reporting Persons and the persons set forth on Schedule A and in Item 2(d) hereto has effected any transactions in the Common Stock during the last 60 days.
     (d) Except as set forth in this Item 5, no person other than each respective record owner referred to herein of the Securities is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Securities.
     (e) As of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities.

 

 

CUSIP NO. 89235K105 Schedule 13D Page 10 of 11
SIGNATURE
          After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
October 10, 2008
Advent Healthcare and Life Sciences II Limited Partnership
By:    Advent International Limited Partnership,
General Partner
 
By:    Advent International Corporation,
General Partner
 
By:    Jarlyth H. Gibson, Assistant Compliance Officer*
Advent Healthcare and Life Sciences II Beteiligung GmbH & Co. KG
By:    Advent International Limited Partnership,
Managing Limited Partner
 
By:    Advent International Corporation,
General Partner
 
By:    Jarlyth H. Gibson, Assistant Compliance Officer*
Advent International Limited Partnership
Advent Partners HLS II Limited Partnership
Advent Partners Limited Partnership
By:    Advent International Corporation,
General Partner
 
By:    Jarlyth H. Gibson, Assistant Compliance Officer*
Advent International Corporation
By:    Jarlyth H. Gibson, Assistant Compliance Officer*
 
*   For all of the above:
         
/s/ Jarlyth H. Gibson      
Jarlyth H. Gibson, Assistant Compliance Officer     

 

 

         
CUSIP NO. 89235K105 Schedule 13D Page 11 of 11
SCHEDULE A
          The name and present principal occupation of each executive officer and director of Advent International Corporation is set forth below. The business address of each executive officer and director of Advent International Corporation is c/o Advent International Corporation, 75 State Street, Boston, Massachusetts 02109. All of the persons listed below are United States citizens.
I. Advent International Corporation
         
    Position with   Principal
    Advent International   Occupation
Name   Corporation   (if different)
Peter A. Brooke
  Chairman    
 
        
Thomas H. Lauer
  Senior Vice President
Managing Director
Chief Operating Officer
Assistant Secretary
Executive Officers’
Committee Member		    
 
        
Ernest G. Bachrach
  Executive Officers’
Committee Member		    
 
        
Humphrey W. Battcock
  Executive Officers’
Committee Member		    
 
        
Ralf Huep
  Executive Officers’
Committee Member		    
 
        
David M. Mussafer
  Director
Executive Officers’
Committee Member		    
 
        
William C. Schmidt
  Executive Officers’
Committee Member		    
 
        
Steven M. Tadler
  Director
Executive Officers’
Committee Member		    
 
        
Janet L. Hennessy
  Senior Vice President
Partner
Chief Financial Officer
Chief Compliance Officer
Assistant Secretary		    
 
        
John F. Brooke
  Director   General Partner of Brooke
Private Equity
 
        
Mark Hoffman
  Director   Chairman of Cambridge
Research Group
 
        
David W. Watson
  Secretary   Attorney